News

Author: Renate Birkeli

Download Our Investor Presentation

Download our presentation

Download presentation

"*" indicates required fields

Calluna Pharma will use the contact details you provide to contact you with regards to offering further information, as well as to keep you updated on our latest developments. You may unsubscribe at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.

Latest news

Latest News Press Releases
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications 

Oslo, Norway, 23 October 2024: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory...

Read more
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board

Executive appointments will drive growth strategy and progression of clinical pipeline Oslo, Norway and Boston, MA, 9 October 2024: Calluna...

Read more